Long-Term Financial Benefits of Drug-Eluting Stents Becoming Evident

NEW YORK, April 28 /PRNewswire/ -- Each year in the United States alone, almost 1 million people with coronary artery disease are treated with a percutaneous coronary procedure (PCI); worldwide the number is about 2.1 million. Up to 50% will experience restenosis -- the re-narrowing of the coronary artery -- within three to six months. To prevent this, stents are delivered into the artery during about 70% of PCI procedures.

According to a new report by Kalorama Information, Major World Markets for Stents Major World Markets for Stents and the Economics of Drug-Eluting Technology, the current market for coronary stents in the seven major world healthcare markets is $4.9 billion.

Recently, stents have been developed that are covered with drugs being released over time in order to reduce the risk of restenosis caused by cellular proliferation. The market effects of these new drug-eluting stents (DES) began in 2003. Today they represent 69.2% of the total coronary stent market, which is expected to grow at a rate of about 4.6% now that the shock that surrounded the alleged DES problems has dissipated.

"Though drug-eluting stents cost 3 to 4 times as much as bare metal stents, when one examines their cost-effectiveness, the case is clear," notes Kalorama analyst Kenneth Krul. "They remain an exciting innovation that will be a major part of cardiovascular intervention technologies over the next ten years, and it should become increasingly evident that DES use does in fact result in reduced long-term healthcare costs and improved economic outcomes."

Kalorama Information's report Major World Markets for Stents Major World Markets for Stents and the Economics of Drug-Eluting Technology focuses on the market applications of current and advanced technologies in the development of coronary stents, with an emphasis on drug-eluting stents. The market analysis covers the seven major world healthcare markets (US, France, Germany, Italy, Japan, Spain and the United Kingdom). Current and future trends, market size, projections, and company profiles are also provided. The report can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Major-Stents-Economics-1646598/.

About Kalorama Information

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. Kalorama routinely assists media with healthcare topics, and can provide experts to speak about markets in the life sciences industry. For more information, contact Andrea Hiller at 212-807-2673 or [email protected], or visit http://www.kaloramaInformation.com.

SOURCE Kalorama Information

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.